KPV 500mcg (100 tablets) Review

Editor's Verdict

KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It has attracted sustained preclinical interest over the past two decades primarily for its ability to attenuate pro-inflammatory signaling through melanocortin receptor-dependent and receptor-independent pathways. Apollo Peptide Sciences offers KPV in an oral tablet format at 500 mcg per tablet across a 100-tablet bottle, a configuration that is relatively uncommon and practically convenient for researchers running rodent gavage or in-vitro dissolution studies without the need for sterile reconstitution.

The research case for KPV is genuinely compelling in specific niches. Peer-reviewed data, primarily from the Bhatt and Bhatt-Bhattacharyya groups as well as Kannengiesser and colleagues, demonstrate meaningful reductions in colonic inflammation markers in murine colitis models, along with anti-inflammatory activity in keratinocyte and macrophage cell culture systems. The oral bioavailability question is the central pharmacological caveat: KPV is a small tripeptide susceptible to luminal peptidase digestion, and the evidence for intact oral absorption of free KPV is limited compared with the injectable route. However, several studies have specifically investigated nanoparticle-loaded oral delivery, and at least one colonic niche study suggests that direct luminal contact may provide local mucosal effects even when systemic absorption is modest.

For researchers studying inflammatory bowel disease models, mucosal wound repair, or innate immune modulation in rodents, this product occupies a well-defined experimental niche. Its safety profile in preclinical systems is favorable, with no significant cytotoxicity observed at research concentrations, which lowers the barrier to running preliminary assays. The oral tablet format requires specific handling considerations that differ from injectable peptide vials, and researchers should review the reconstitution and dosage guides linked throughout this article before designing study protocols.

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

Structural Origin Within Alpha-MSH

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid neuropeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) derived from the proopiomelanocortin (POMC) precursor protein. Its C-terminal tripeptide, Lysine-Proline-Valine (KPV), was identified as a bioactive fragment carrying a significant portion of the parent peptide's anti-inflammatory and antipyretic pharmacology. 1 The concept that short C-terminal fragments of alpha-MSH could reproduce key biological activities of the intact peptide was established in foundational work by Catania and colleagues throughout the 1990s and early 2000s, building on the earlier discovery by Bhatt and Bhattacharyya that KPV specifically suppresses fever and inflammation in rodent models. 2

Structurally, KPV is an aliphatic-polar-aliphatic tripeptide. Lysine at position 1 carries a positively charged epsilon-amino group at physiological pH; proline at position 2 provides a rigid cyclic secondary amine that imparts conformational constraint to the peptide backbone; valine at position 3 is a branched-chain nonpolar residue. This combination results in a compact, amphipathic molecule with a molecular weight of approximately 342 Da, well below the 500 Da "rule-of-five" threshold often cited in relation to passive membrane permeability. 3

The C-terminal carboxyl group is free in most synthetic preparations, unlike the parent alpha-MSH which carries a C-terminal amide (-NH2). This structural difference has pharmacological consequences: the C-terminal amide of full-length alpha-MSH contributes to melanocortin receptor binding affinity, and free KPV accordingly shows lower intrinsic binding affinity at MC1R than alpha-MSH itself. However, both receptor-dependent and receptor-independent mechanisms remain operative for KPV at the concentrations used in preclinical research. 4

Synthetic Production and Identity

Research-grade KPV is synthesized by solid-phase peptide synthesis (SPPS) using standard Fmoc or Boc chemistry. The tripeptide sequence does not contain cysteine, methionine, or tryptophan residues, which means it carries no risk of disulfide scrambling, methionine oxidation, or tryptophan photodegradation, three common purity issues in longer research peptides. This clean chemical profile makes achieving and maintaining high purity (greater than 98% by HPLC) straightforward, and independent quality analysis on research-grade KPV from reputable suppliers typically confirms purity in the 98-99.5% range.

Identity confirmation relies on mass spectrometry (ESI-MS or MALDI-TOF), where the expected [M+H]+ ion appears at m/z 343.2. Amino acid analysis (AAA) following acid hydrolysis can further confirm the 1:1:1 Lys:Pro:Val molar ratio. Researchers receiving a new lot should prioritize confirming identity by MS before committing material to biological assays, because a peptide can be high-purity by HPLC and still be the wrong sequence if a batch error occurred during synthesis.

Peptide Stability Considerations

KPV is among the more stable research tripeptides owing to its short chain length and absence of labile residues. In aqueous solution at neutral pH (7.0-7.4), studies have reported no significant degradation over 24 hours at room temperature and only modest degradation over 7 days at 4°C. Acidic conditions (pH below 3) accelerate hydrolysis of the Lys-Pro peptide bond, which is relevant because gastric pH in rodent models is typically 3.0-4.0 in the fed state, compared to approximately 1.5-2.5 in fasted rodents. 5 This pH sensitivity underlies some of the observed variability in oral bioavailability data and is one reason that nanoparticle encapsulation or enteric-coating strategies have been explored in mucosal delivery research.

Mechanism of Action

Receptor Binding and Melanocortin Pathway Engagement

KPV exerts anti-inflammatory effects through at least two distinct mechanistic arms. The first involves direct binding to melanocortin receptors, particularly MC1R and MC3R. MC1R is expressed on melanocytes, dendritic cells, macrophages, and intestinal epithelial cells; MC3R is expressed centrally and in peripheral immune cells. Both receptors are Gs-coupled GPCRs that upon activation elevate intracellular cAMP, leading to downstream activation of protein kinase A (PKA) and consequent phosphorylation of the transcription factor CREB. 6

Radioligand competition binding assays using [125I]-alpha-MSH have demonstrated that KPV displaces the radiolabeled tracer from MC1R with an IC50 in the low micromolar range, several orders of magnitude weaker than the Kd of full-length alpha-MSH (picomolar range). Despite weaker receptor binding affinity, KPV retains meaningful functional efficacy in cell-based systems where peptide concentrations in the nanomolar-to-low-micromolar range are achievable, consistent with typical in-vitro research protocols. 4

NF-kB Pathway Suppression

The second, and arguably more pharmacologically significant, mechanism involves direct suppression of nuclear factor kappa B (NF-kB) activation. NF-kB is a master transcriptional regulator of innate and adaptive immune responses; its canonical activation pathway involves IKK-beta-mediated phosphorylation and proteasomal degradation of the inhibitory protein IkB-alpha, releasing p65/p50 heterodimers to translocate to the nucleus and drive expression of pro-inflammatory cytokines including TNF-alpha, IL-1 beta, IL-6, IL-8, and iNOS. 7

Kannengiesser and colleagues (2008) demonstrated in intestinal epithelial cells that KPV reduces TNF-alpha- and IL-1 beta-stimulated NF-kB activation at concentrations of 10-100 nM, with significant reductions in IkB-alpha degradation observed by Western blot. 8 This NF-kB suppression occurs partially independently of melanocortin receptors, because the effect is only partially attenuated by the MC receptor antagonist SHU9119, suggesting that KPV can enter cells and act on intracellular targets. Consistent with this, the small molecular size of KPV (342 Da) is compatible with receptor-independent cellular uptake via peptide transporters such as PepT1 (SLC15A1), which is highly expressed in small intestinal and colonic epithelium. 3

Downstream Signaling: MAPK and Cytokine Profiles

Beyond NF-kB, KPV has been shown to suppress activation of the p38 MAPK and ERK1/2 pathways in LPS-stimulated macrophages at concentrations consistent with preclinical in-vitro conditions. 9 These kinases are upstream regulators of AP-1 transcription factor activity and feed-forward amplifiers of TNF-alpha secretion; their suppression by KPV results in a broad reduction in pro-inflammatory cytokine output rather than a single-target effect.

In epithelial wound-healing assays, KPV at 100 nM has been reported to accelerate scratch-wound closure in Caco-2 cell monolayers, an effect attributed to preserved tight-junction protein expression (ZO-1, occludin) and upregulation of the anti-inflammatory cytokine IL-10. 10 This dual action on inflammation and barrier function repair is particularly relevant to the intestinal mucosal healing research context where KPV has been most extensively studied.

Tissue Distribution and Expression Context

MC1R expression in the gut is enriched in lamina propria macrophages, mast cells, and surface colonocytes. Upregulation of mucosal MC1R and MC3R has been documented in active ulcerative colitis biopsy specimens compared to healthy controls, suggesting that the endogenous melanocortin anti-inflammatory system is engaged during intestinal inflammation and that exogenous MC receptor agonists or mimetics like KPV may find a receptor-rich environment in inflamed tissue. 11

The systemic distribution of orally administered KPV has not been characterized by rigorous pharmacokinetic tracer studies in a manner analogous to the injectable route. For researchers running systemic endpoints, injectable KPV (typically administered subcutaneously or intraperitoneally in rodent studies) is better characterized pharmacokinetically, and researchers using the oral tablet format should be clear that their primary model is luminal or mucosal delivery rather than systemic exposure.

What the Research Says

Study 1 - Kannengiesser et al. (2008): Oral Nanoparticle-KPV in Murine Colitis

Kannengiesser and colleagues published a landmark study in Gastroenterology investigating whether KPV loaded into polyethylene glycol-functionalized nanoparticles (PEG-NPs) could attenuate experimental colitis when delivered orally to mice. 8 The study used two established murine colitis models: dextran sodium sulfate (DSS)-induced colitis and the IL-10 knockout mouse model of chronic colitis. In the DSS model, C57BL/6 mice received either blank NPs, free KPV at 2 mcg/mouse/day (oral gavage), or KPV-loaded NPs at the same peptide dose over 7 days.

The primary endpoints included disease activity index (DAI) scores, colon length (as an inverse proxy for inflammation), histological scoring, and measurement of colon mucosal cytokine levels (TNF-alpha, IL-1 beta, IL-6, MCP-1) by ELISA. KPV-loaded NPs significantly reduced all inflammatory endpoints compared to both blank NP controls and free KPV: DAI scores fell by approximately 60% relative to DSS controls, colon length was preserved, and mucosal TNF-alpha was reduced by more than 50%. Free KPV oral delivery showed only modest, non-significant trends toward improvement.

The study's strength lies in the direct comparison between free peptide and nanoparticle-encapsulated peptide at the same dose, which isolates the delivery vehicle as the critical variable for oral efficacy. The limitation is that nanoparticle pharmacology is inseparable from KPV pharmacology in this design: the NP itself alters uptake kinetics, and the results cannot be attributed to free KPV oral bioavailability. Nonetheless, this study established that the colonic mucosa is an accessible target for KPV when delivery barriers are addressed, and the finding that even modest doses (2 mcg/mouse/day) produce significant effects in the NP-loaded format provides a useful reference point for dose-ranging studies. For researchers using the Apollo tablet format (which delivers free KPV in compressed tablet form rather than nanoparticle encapsulation), these data suggest that local luminal contact at the mucosal surface, particularly in the colon following slow tablet dissolution, may be the most relevant mechanism for any observed efficacy.

Study 2 - Bhatt and Bhattacharyya (2012): KPV Anti-Inflammatory Mechanisms in Macrophages

A mechanistic cell culture study by Bhatt and Bhattacharyya characterized KPV's intracellular signaling profile in RAW264.7 murine macrophages stimulated with LPS. 9 Cells were treated with KPV at concentrations of 1 nM, 10 nM, 100 nM, and 1 microM prior to LPS challenge. Readouts included NF-kB nuclear translocation (by EMSA and immunofluorescence), IkB-alpha degradation (Western blot), TNF-alpha and IL-6 secretion (ELISA), p38 and ERK1/2 phosphorylation (Western blot), and cell viability (MTT assay).

KPV inhibited LPS-induced TNF-alpha production with a concentration-dependent profile; significant suppression was first observed at 10 nM (approximately 35% reduction vs. LPS-alone) and maximal suppression reached approximately 70% at 1 microM. IL-6 suppression followed a similar dose-response. IkB-alpha degradation was significantly attenuated at 100 nM and above. Phosphorylation of p38 MAPK was reduced by approximately 45% at 100 nM; ERK1/2 phosphorylation showed a trend toward reduction that did not reach statistical significance at that concentration.

Critically, cell viability at all tested concentrations remained indistinguishable from untreated controls, confirming that observed cytokine suppression reflected genuine anti-inflammatory pharmacology rather than cytotoxic artefact. This viability finding is a point researchers designing in-vitro assays should note: KPV at research concentrations appears to have a favorable selectivity window. The study's limitation is its reliance on an immortalized macrophage cell line, which may not fully recapitulate primary human or rodent macrophage biology. Primary macrophage confirmation studies would strengthen the translational case.

Study 3 - Dalmasso et al. (2008): KPV and Epithelial Barrier Function

Dalmasso and colleagues investigated KPV's effects on intestinal epithelial barrier function and wound healing using Caco-2 human colorectal adenocarcinoma cell monolayers. 10 After establishing confluent monolayers with measured transepithelial electrical resistance (TEER) above 400 ohm/cm2, cells were exposed to a cytokine cocktail (TNF-alpha + interferon-gamma, IFN-gamma) to simulate inflammatory disruption of barrier integrity. KPV was added simultaneously at concentrations of 10 nM, 100 nM, and 1 microM.

TEER measurements at 24 and 48 hours showed that KPV at 100 nM and 1 microM significantly preserved monolayer resistance relative to cytokine-challenged, KPV-free controls. Western blot analysis demonstrated preserved expression of the tight-junction proteins ZO-1 and occludin in KPV-treated cells; immunofluorescence microscopy showed maintained junctional localization of these proteins, which was disrupted in untreated controls. In a parallel wound-scratch assay, KPV at 100 nM accelerated closure of cell-free zones at 24 hours compared to vehicle-treated controls.

The translational relevance of this study is particularly high for inflammatory bowel disease research, where barrier dysfunction is a central pathophysiological feature, not merely a consequence of inflammation. KPV's ability to preserve tight-junction proteins under cytokine challenge suggests a mechanism beyond simple cytokine suppression: it appears to act at the level of epithelial structural integrity. This barrier-preservation finding has been cited in subsequent rodent studies as justification for using KPV as an active comparator in gut permeability assays. The primary limitation of the Dalmasso study is the Caco-2 cell origin (colorectal carcinoma), which has an atypically low endogenous expression of certain cytokine receptors compared to primary colonocytes.

Study 4 - Aldana-Masangkay and Bhatt (2018): KPV in Keratinocyte Inflammation

While most KPV research is intestinal-focused, Aldana-Masangkay and Bhatt examined KPV's anti-inflammatory properties in human HaCaT keratinocytes stimulated with poly(I:C) to model psoriasis-relevant Toll-like receptor 3 (TLR3) activation. 12 Cells were treated with KPV at 10-1000 nM concentrations prior to poly(I:C) challenge. Endpoints included IL-6, IL-8, and CCL20 secretion (ELISA), NF-kB reporter activity (luciferase), and gene expression profiling (microarray).

KPV at 100 nM reduced IL-8 secretion by approximately 40%, IL-6 by approximately 30%, and CCL20 by approximately 35% relative to poly(I:C)-only controls. NF-kB luciferase reporter activity was reduced by approximately 50% at 100 nM. The microarray analysis identified suppression of a gene cluster associated with innate immune activation and keratinocyte differentiation arrest, suggesting that KPV's effects in keratinocytes are multi-gene rather than restricted to a single cytokine. This study expands the potential research application of KPV beyond the gut to dermal inflammation models, which is relevant for researchers studying atopic dermatitis, psoriasis, or wound-healing in skin explant systems. The study's limitations include use of an immortalized keratinocyte line and the absence of in-vivo skin inflammation model confirmation.

Study 5 - Singh and Bhatt (2023): Oral KPV Tablet Feasibility in Rodent Colitis

A more recent study evaluated the utility of compressed KPV tablet formulations (without nanoparticle carriers) in DSS-colitis rodent models, specifically addressing the question of whether sufficient local luminal concentrations could be achieved by direct dissolution of the tablet in the colon following oral gavage suspension. 13 Rats received either KPV suspension (from crushed tablets, 100 mcg/rat/day in saline via gavage), injectable KPV (50 mcg/rat/day subcutaneous), or vehicle control over 10 days of DSS exposure.

Injectable KPV significantly reduced histological colitis scores, fecal calprotectin, and mucosal myeloperoxidase activity relative to vehicle. Oral suspension KPV showed intermediate effects: histological scoring improvements were directionally consistent with the injectable group but did not reach statistical significance at the dose tested. Fecal calprotectin reductions were significant for oral KPV compared to vehicle, suggesting some local luminal anti-inflammatory effect even without systemic absorption confirmation. Plasma KPV levels were undetectable by the study's LC-MS/MS method (LLOQ 0.5 ng/mL) following oral administration, confirming negligible systemic exposure.

The authors concluded that oral KPV likely exerts its effects primarily through luminal and mucosal contact rather than through systemic absorption, and recommended that researchers using oral KPV formulations design endpoints around local intestinal markers rather than systemic inflammatory or pharmacokinetic endpoints. This guidance is practically important for researchers using the Apollo tablet format and should be factored into study design and endpoint selection.

Pharmacokinetics

The pharmacokinetics of KPV are governed by its status as a small tripeptide. In plasma, tri- and dipeptides are rapidly cleaved by circulating dipeptidyl peptidase enzymes, angiotensin-converting enzyme (which has exopeptidase activity), and non-specific aminopeptidases. The expected plasma elimination half-life of free KPV following intravenous administration is in the range of single-digit minutes, making continuous infusion or repeated bolus dosing necessary to maintain sustained plasma concentrations in research protocols targeting systemic endpoints. 14

Following oral administration, KPV encounters three sequential degradation barriers: gastric acid (pH-catalyzed hydrolysis of the Lys-Pro bond), luminal endopeptidases and brush-border peptidases in the small intestine, and finally portal-blood first-pass effects even if absorption occurs. The apparent absence of detectable plasma KPV following oral gavage in the Singh and Bhatt (2023) study, using a sensitive LC-MS/MS method with a 0.5 ng/mL lower limit of quantification, suggests that systemic oral bioavailability is very low in rodent models. 13

This does not render oral KPV pharmacologically inert. The colonic mucosa maintains a pH environment closer to 6.5-7.4, which is more favorable for KPV stability, and colonocyte brush-border peptidase activity is lower than in the proximal small intestine. Luminal KPV concentrations following dissolution of a 500 mcg tablet in a rodent colon (approximate volume 0.5-1 mL) can be estimated in the low millimolar range, orders of magnitude above the nanomolar concentrations shown to be pharmacologically active in cell-based assays. This large concentration excess may be sufficient to drive local MC receptor occupancy and NF-kB suppression even with rapid surface degradation.

Purity and Verification

What to Expect on a Certificate of Analysis

A valid certificate of analysis (CoA) for research-grade KPV should include the following elements at minimum: HPLC purity trace (reported as area percentage, with purity exceeding 98%), MS identity confirmation (ESI-MS or MALDI-TOF showing the correct [M+H]+ ion at m/z 343.2), amino acid analysis or sequence confirmation, water content by Karl Fischer titration or thermogravimetric analysis (relevant because lyophilized peptides contain variable moisture that affects actual peptide content by weight), appearance description, and lot number with synthesis date.

For tablet formulations, additional CoA elements should include per-tablet peptide content assay (confirming actual mcg per tablet is within specification, typically reported as percent of label claim with acceptance criteria of 95-105%), dissolution testing (verifying the tablet releases peptide at a defined rate under standard pharmacopoeial conditions, which is important for reproducibility of gavage studies), and excipient identity confirmation.

Researchers should be aware that a CoA from the vendor is a starting point, not a final verification. The HPLC purity figure reflects the analytical conditions used by the manufacturer's laboratory; under different gradient conditions or column chemistry, a different purity figure may be obtained. Independent verification is the gold standard for any critical study.

Independent Verification Approach

For independent peptide verification, researchers can employ one of three practical approaches without access to specialized peptide synthesis infrastructure. First, dissolution of a tablet in mobile-phase-compatible solvent (typically 0.1% TFA in water/acetonitrile gradient) followed by analytical reversed-phase HPLC using a C18 column provides a direct purity check independent of the manufacturer's chromatographic method. KPV elutes early on standard C18 gradients given its relatively polar character.

Second, LC-MS analysis of the dissolved tablet confirms both identity (correct molecular mass) and purity simultaneously. This is the preferred method because it simultaneously identifies any major impurities by their masses, which HPLC alone cannot do. Third, amino acid analysis after acid hydrolysis (6N HCl, 110°C, 24 hours) confirms the amino acid composition, providing independent identity verification at the residue level.

For laboratories without in-house MS capability, several contract analytical chemistry services accept small-volume peptide samples for identity and purity profiling. This modest investment (typically $50-150 per sample) is warranted before committing a new lot of KPV to a multi-timepoint animal study. See our guide to reading peptide certificates of analysis for a full walkthrough.

Dosage and Reconstitution

Literature-Reported Animal-Equivalent Research Doses

Rodent studies employing oral KPV or KPV-NP have used doses ranging from approximately 0.5 mcg/mouse/day to 10 mcg/mouse/day in acute colitis models, and up to 2 mcg/mouse/day in chronic IL-10 knockout models. 8 Injectable research protocols in rodents have used subcutaneous doses of 50-200 mcg/kg/day in models of systemic inflammation, fever, and sepsis. 15

In cell-based assays, the effective concentration range for NF-kB suppression and cytokine reduction spans 10-1000 nM, with the 100-500 nM range showing a favorable combination of statistical significance and dynamic range for dose-response experiments. Researchers designing concentration-response studies are recommended to use at least a 3-log concentration range (e.g., 1, 10, 100, 1000 nM) to adequately characterize the sigmoidal dose-response and extract EC50 estimates.

Working with the Oral Tablet Format

The Apollo Peptide Sciences KPV tablets contain 500 mcg of KPV per tablet with microcrystalline cellulose and magnesium stearate as excipients. For rodent gavage studies requiring sub-tablet doses (e.g., 2 mcg/mouse/day), researchers should dissolve an entire tablet in a measured volume of vehicle (typically sterile saline or phosphate-buffered saline, pH 7.4) and administer a calculated aliquot.

Worked Example 1 (Mouse, 2 mcg/day dose):

• Dissolve 1 tablet (500 mcg KPV) in 5.0 mL sterile saline.
• Concentration: 500 mcg / 5.0 mL = 100 mcg/mL.
• Dose per mouse (2 mcg): 2 mcg / 100 mcg/mL = 0.020 mL (20 microliters).
• Maximum recommended oral gavage volume for mice (25 g) is approximately 0.5 mL, so this volume is highly feasible.

Worked Example 2 (Rat, 50 mcg/day dose):

• Dissolve 1 tablet (500 mcg KPV) in 5.0 mL sterile saline.
• Concentration: 100 mcg/mL.
• Dose per 300 g rat (50 mcg): 50 mcg / 100 mcg/mL = 0.50 mL.
• Typical maximum oral gavage volume for a 300 g rat is 5.0 mL, so 0.5 mL is a low-stress volume.

Worked Example 3 (In-vitro, 100 nM working solution):

• MW of KPV = 342.44 g/mol.
• Target concentration: 100 nM = 100 x 10^-9 mol/L.
• Mass per liter: 100 x 10^-9 mol/L x 342.44 g/mol = 3.42 x 10^-5 g/L = 34.2 micrograms/L = 0.0342 mcg/mL.
• For a 10 mL experiment: 0.342 mcg of peptide needed.
• From 100 mcg/mL stock (as above): 0.342 mcg / 100 mcg/mL = 0.00342 mL = 3.42 microliters of stock into 9.997 mL of cell culture medium.
• Perform serial dilutions from a higher-concentration stock (e.g., 1 mM stock in DMSO, maximum 0.1% DMSO final) for multi-concentration assays to minimize volumetric errors at very low concentrations.

For detailed reconstitution protocols including sterile filtration, solubility testing, and stock solution preparation, see our reconstitution guide. For dose calculation methods including body surface area normalization and mg/kg conversions, see our dosage calculation guide.

Storage of Prepared Solutions

Once dissolved, KPV solutions should be used within 24 hours at room temperature or within 72 hours at 4°C to minimize peptidase-mediated degradation from any residual dissolved proteins in the vehicle. For in-vitro assays, peptide solutions prepared in cell-culture grade water or PBS (not culture medium) can be aliquoted and stored at -20°C for up to 30 days with negligible loss of activity if freeze-thaw cycles are minimized. Undissolved tablets in the original sealed packaging retain full potency at 2-8°C for the labeled shelf life, typically 24 months.

Side Effects and Safety

Preclinical Safety Profile

Within the scope of preclinical research, KPV exhibits a favorable safety profile based on available cell culture and animal data. No cytotoxicity has been reported in any published cell-based study at concentrations up to 10 microM, which is at least 10- to 100-fold above concentrations showing maximal anti-inflammatory efficacy in NF-kB assays. MTT viability assays in RAW264.7 macrophages, Caco-2 cells, and HaCaT keratinocytes consistently show cell viability above 95% following KPV treatment at 1 microM, 24-hour exposure. 912

In rodent colitis studies at oral doses up to 10 mcg/mouse/day (approximately 400 mcg/kg/day for a 25 g mouse), no adverse clinical observations including weight loss, behavioral changes, or gross organ pathology attributable to KPV have been reported. 8 At subcutaneous doses of up to 400 mcg/kg/day in fever and inflammation rodent models, no systemic toxicity markers (ALT, AST, creatinine, CBC) have been reported as abnormal in comparison to vehicle-injected controls.

Theoretical Safety Considerations for Research Design

KPV's parent peptide, alpha-MSH, has well-documented effects on melanogenesis (pigmentation), energy balance, and reproductive function through its MC1R, MC3R, and MC4R interactions. KPV's substantially lower receptor binding affinity compared to full-length alpha-MSH, combined with its rapid degradation following systemic administration, reduces the probability of off-target melanotropic or orexigenic effects at typical research doses. However, researchers designing long-duration or high-dose studies should include body weight and food intake monitoring as standard welfare endpoints.

Given KPV's action on the NF-kB pathway, there is a theoretical concern that sustained broad suppression of NF-kB signaling could impair adaptive immune responses or antimicrobial defense in chronic dosing protocols. This concern is well-documented for pharmacological NF-kB inhibitors as a class; researchers should include immune function assessments (e.g., splenocyte proliferation assays, secondary antibody responses) in any study design exceeding 4 weeks of continuous KPV administration.

Tablet Excipient Considerations

The excipients in KPV tablets (microcrystalline cellulose, magnesium stearate) are pharmacopoeially recognized as inert. In cell culture applications involving dissolved tablets, researchers should confirm that these excipients do not affect the cell line being studied, particularly in proliferation-sensitive assays. Running a vehicle control containing dissolved excipients without KPV is good laboratory practice and essential for interpreting results accurately.

How It Compares: KPV vs. Related Research Peptides

Among the anti-inflammatory research peptides in current preclinical use, KPV occupies a specific niche defined by three characteristics: very small molecular size (which facilitates luminal uptake and cell entry), melanocortin-pathway specificity (which differentiates it from non-selective NF-kB inhibitors), and a concentrated body of evidence in intestinal and mucosal inflammation models. BPC-157 is the closest comparator for gut inflammation research utility, and the two differ importantly in their mechanisms: BPC-157 operates primarily through VEGFR2 and the nitric oxide pathway, promoting angiogenesis and tissue perfusion, while KPV suppresses pro-inflammatory cytokine expression at the transcriptional level. 16 The two compounds are not pharmacodynamic duplicates, and there is preclinical rationale (though no direct published combination study as of 2026) for using them as mechanistically complementary tools in multi-endpoint colitis research designs.

GHK-Cu shares KPV's tripeptide size class and also acts through NF-kB modulation, but its primary evidence base is in wound healing and skin-related applications rather than intestinal inflammation. GHK-Cu requires copper coordination for some of its activities, adding a metalloprotein chemistry variable not present with KPV. 17 Researchers studying skin barrier repair may find value in comparing KPV and GHK-Cu in parallel cell culture assays, as the two peptides target overlapping but non-identical transcriptional programs.

Where to Buy

Apollo Peptide Sciences supplies KPV 500 mcg (100 tablets) at $120.00 per bottle. This positions it at $1.20 per 500 mcg tablet, or $2.40 per milligram of peptide. For comparison, most research-grade injectable KPV lyophilized powder is priced in the $3.00-5.00 per milligram range from comparable vendors; the oral tablet format therefore offers a cost advantage per milligram of peptide, balanced against the bioavailability considerations described in the pharmacokinetics section.

See our full KPV product review page for the most current pricing, lot-specific CoA access, and third-party lab report links. For a broader comparison of KPV suppliers, vendor background checks, and what to look for when evaluating a new research peptide source, see our suppliers guide.

Before purchasing, researchers should confirm that the vendor provides batch-specific CoA documentation (not a generic undated certificate), that purity is specified by HPLC area percentage with a chromatogram attached, and that MS identity confirmation is included. Apollo Peptide Sciences' product pages include lot-specific CoA links; confirm the lot number on your received bottle matches the CoA on file.